Running performance at high running velocities is impaired but V'O_{2max} and peripheral endothelial function are preserved in IL-6^{−/−} mice

doi:10.1371/journal.pone.0088333

Running performance at high running velocities is impaired but V'O_{2max} and peripheral endothelial function are preserved in IL-6^{−/−} mice

Communities & Collections

pcg.skipToMenu

Running performance at high running velocities is impaired but V'O_{2max} and peripheral endothelial function are preserved in IL-6^{−/−} mice

View Usage Statistics

Show full item record

dc.contributor.author	Wojewoda, Marta [SAP14007502]	pl
dc.contributor.author	Kmiecik, Katarzyna [SAP14011229]	pl
dc.contributor.author	Ventura-Clapier, Renée	pl
dc.contributor.author	Fortin, Dominique	pl
dc.contributor.author	Onopiuk, Marta	pl
dc.contributor.author	Jakubczyk, Justyna	pl
dc.contributor.author	Sitek, Barbara [SAP14005869]	pl
dc.contributor.author	Fedorowicz, Andrzej [SAP14003780]	pl
dc.contributor.author	Majerczak, Joanna	pl
dc.contributor.author	Kamiński, Karol	pl
dc.contributor.author	Chłopicki, Stefan [SAP20000969]	pl
dc.contributor.author	Żołądź, Jerzy Andrzej	pl
dc.date.accessioned	2015-07-31T08:00:00Z
dc.date.available	2015-07-31T08:00:00Z
dc.date.issued	2014	pl
dc.identifier.uri	http://ruj.uj.edu.pl/xmlui/handle/item/14336
dc.language	eng	pl
dc.rights	Udzielam licencji. Uznanie autorstwa 4.0 Międzynarodowa	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/pl/legalcode	*
dc.title	Running performance at high running velocities is impaired but V'O_{2max} and peripheral endothelial function are preserved in IL-6^{−/−} mice	pl
dc.type	JournalArticle	pl
dc.description.physical	1-10	pl
dc.abstract.en	It has been reported that IL-6 knockout mice (IL-6^{−/−}) possess lower endurance capacity than wild type mice (WT), however the underlying mechanism is poorly understood. The aim of the present work was to examine whether reduced endurance running capacity in IL-6^{−/−} mice is linked to impaired maximal oxygen uptake (V′O_{2max}), decreased glucose tolerance, endothelial dysfunction or other mechanisms. Maximal running velocity during incremental running to exhaustion was significantly lower in IL-6−/− mice than in WT mice (13.00±0.97 m.min^{-1} vs. 16.89±1.15 m.min^{-1}, P<0.02, respectively). Moreover, the time to exhaustion during running at 12 m.min^{-1} in IL-6^{−/−} mice was significantly shorter (P<0.05) than in WT mice. V′O_{2max} in IL-6^{−/−} (n = 20) amounting to 108.3±2.8 ml.kg^{-1}.min^{-1} was similar as in WT mice (n = 22) amounting to 113.0±1.8 ml.kg^{-1}.min^{-1}, (P = 0.16). No difference in maximal COX activity between the IL-6^{−/−} and WT mice in m. soleus and m. gastrocnemius was found. Moreover, no impairment of peripheral endothelial function or glucose tolerance was found in IL-6^{−/−} mice. Surprisingly, plasma lactate concentration during running at 8 m.min−1 as well at maximal running velocity in IL-6^{−/−} mice was significantly lower (P<0.01) than in WT mice. Interestingly, IL-6^{−/−} mice displayed important adaptive mechanisms including significantly lower oxygen cost of running at a given speed accompanied by lower expression of sarcoplasmic reticulum Ca^{2+}-ATPase and lower plasma lactate concentrations during running at submaximal and maximal running velocities. In conclusion, impaired endurance running capacity in IL-6^{−/−} mice could not be explained by reduced V′O_{2max}, endothelial dysfunction or impaired muscle oxidative capacity. Therefore, our results indicate that IL-6 cannot be regarded as a major regulator of exercise capacity but rather as a modulator of endurance performance. Furthermore, we identified important compensatory mechanism limiting reduced exercise performance in IL-6^{−/−} mice.	pl
dc.description.volume	9	pl
dc.description.number	2	pl
dc.description.points	40	pl
dc.identifier.doi	10.1371/journal.pone.0088333	pl
dc.identifier.eissn	1932-6203	pl
dc.title.journal	PLoS ONE	pl
dc.language.container	eng	pl
dc.affiliation	Wydział Lekarski : Zakład Farmakologii Doświadczalnej	pl
dc.affiliation	Pion Rektora : Jagiellońskie Centrum Rozwoju Leków	pl
dc.subtype	Article	pl
dc.identifier.articleid	e88333	pl
dc.rights.original	CC-BY; otwarte czasopismo; ostateczna wersja wydawcy; w momencie opublikowania; 0;	pl
dc.identifier.project	ROD UJ / P	pl
.pointsMNiSW	[2014 A]: 40